GlassScriptPhysician profile
John Peter Heinen
NPI 1427096643
$1,149.73
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $727 · 2023: $14.69 · 2024: $16.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.34 | 2021-2024 | |
| Sk Life Science, INC. | $179.51 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $131.60 | 2021 | |
| Lundbeck LLC | $94.30 | 2021-2022 | |
| Amgen INC. | $75.05 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $63.21 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $54.90 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $47.31 | 2022 | |
| Kyowa Kirin, INC. | $46.37 | 2021 | |
| Lilly USA, LLC | $44.58 | 2022 | |
| Ucb, INC. | $41.29 | 2022 | |
| Aquestive Therapeutics, INC. | $34.22 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.81 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.57 | 2022 | |
| Impel Pharmaceuticals INC. | $16.44 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $16.10 | 2022 | |
| Abbott Laboratories | $14.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.69 | 2023 | Nuedexta |
| Supernus Pharmaceuticals, INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Heinen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.